Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Viktoriya Stalbovskaya
JAK Inhibition With Ruxolitinib Versus Best Available Therapy for Myelofibrosis
New England Journal of Medicine
Medicine
Related publications
Cost-Effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain
Journal of Health Economics and Outcomes Research
Primary Myelofibrosis Associated Glomerulopathy: Significant Improvement After Therapy With Ruxolitinib
BMC Nephrology
Nephrology
Efficacy of Ruxolitinib for Myelofibrosis
Expert Opinion on Pharmacotherapy
Medicine
Pharmacology
Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Ruxolitinib as an Emerging Treatment in Myelofibrosis
Blood and Lymphatic Cancer: Targets and Therapy
Placebo Versus Best-Available-Therapy Control Group in Clinical Trials for Pharmacologic Therapies: Which Is Better?
Proceedings of the American Thoracic Society
Sweet Syndrome Successfully Treated With Ruxolitinib in JAK-2 Positive Myeloproliferative Disorder
Safety and Efficacy of Ruxolitinib in Myelofibrosis Patients Without Splenomegaly
British Journal of Haematology
Hematology
Definition and Management of Ruxolitinib Treatment Failure in Myelofibrosis
Blood Cancer Journal
Oncology
Hematology